Published on

The guanylate cyclase C agonist, linaclotide (Linzess), doubled weekly bowel movements among children age 6 and younger, helping to treat pediatric patients with functional constipation, according to a study published in Lancet Gastroenterology & Hepatology. As a recently approved treatment option, linaclotide demonstrated improvement in frequency over placebo with 57% of patients in the treatment group experiencing a spontaneous bowel movement within the first 48 hours of receiving the drug. Authors also observed improvement in a range of other symptoms associated with functional constipation in pediatric patients 6-17 years of age, such as straining and bloating. In terms of adverse events, diarrhea was reported in 4% of patients in the linaclotide group, and dehydration was reported in one patient among the 328 participants.

Back to normal: Constipation affects up to 30% of children and leads to visits to the urgent care and the pediatrician. More options for treatment means more satisfied parents, better quality of life, and fewer days off school.

Linaclotide Relieves Constipation in Kids